The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression
Abstract
Objective To assess the efficacy and safety of subcutaneous ketamine for geriatric treatment-resistant depression. Secondary aims were to examine if repeated treatments were safe and more effective in inducing or prolonging remission than a single treatment. Methods In this double-blind, controlled, multiple-crossover study with a 6-month follow-up (randomized controlled trial [RCT] phase), 16 participants (≥60 years) with treatment-resistant depression who relapsed after remission or did not remit in the RCT were administered an open-label phase. Up to five subcutaneous doses of ketamine (0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg) were administered in separate sessions (≥1 week apart), with one active control (midazolam) randomly inserted (RCT phase). Twelve ketamine treatments were given in the open-label phase. Mood, hemodynamic, and psychotomimetic outcomes were assessed by blinded raters. Remitters in each phase were followed for 6 months. Results Seven of 14 RCT-phase completers remitted with ketamine treatment. Five remitted at doses below 0.5 mg/kg. Doses ≥ 0.2 mg/kg were significantly more effective than midazolam. Ketamine was well tolerated. Repeated treatments resulted in higher likelihood of remission or longer time to relapse. Conclusion Results provide preliminary evidence for the efficacy and safety of ketamine in treating elderly depressed. Dose titration is recommended for optimizing antidepressant and safety outcomes on an individual basis. Subcutaneous injection i…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Improvement in depressive symptoms”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · cites this paper as George et al. (2017)
In the citing paper
“The results reported acute response and remission rates of 68.8% in 11 of 16 participants”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · cites this paper as George et al. (2017)
In the citing paper
“causing discrete increases in heart rate and blood pressure, and occasional reports of mild neurological symptoms.”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · cites this paper as George et al. (2017)
In the citing paper
“concluding that in general, subcutaneously administered ketamine in older patients was effective, safe and well tolerated”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · cites this paper as George et al. (2017)
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Depression, chronic diseases, and decrements in health: results from the World Health Surveys
Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., & Ustun, B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61415-9 · Cited by 4,070
Fiske, A., Wetherell, J. L., & Gatz, M. (2009) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.032408.153621 · Cited by 2,353
CUMULATIVE ILLNESS RATING SCALE
Linn, B. S., Linn, M. W., & Gurel, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,332
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Tedeschini, E., Levkovitz, Y., Iovieno, N., Ameral, V. E., Nelson, J. C., & Papakostas, G. I. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06531 · Cited by 269
Loo, C. K. A., Gálvez, V., O’Keefe, E. J., Mitchell, P. B., Hadzi‐Pavlovic, D., Leyden, J., Harper, S., Somogyi, A. A., Lai, R., Weickert, C. S., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12572 · Cited by 258
Self-citationMeta-analysis of the Brief Psychiatric Rating Scale factor structure.
Shafer, A. (2005) · Psychological Assessment · doi:10.1037/1040-3590.17.3.324 · Cited by 255
Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv124 · Cited by 226
Self-citationIbrahim, L. A., Diazgranados, N., Luckenbaugh, D. A., Machado‐Vieira, R., Baumann, J., Mallinger, A. G., & Zarate, C. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.03.019 · Cited by 191
Chandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158
Allen, A. P., Naughton, M., Dowling, J., Walsh, A., Ismail, F., Shorten, G., Scott, L., McLoughlin, D. M., Cryan, J. F., Dinan, T. G., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.033 · Cited by 138
Ketamine as a new treatment for depression: A review of its efficacy and adverse effects
Katalinic, N., Lai, R., Somogyi, A. A., Mitchell, P. B., Glue, P., & Loo, C. K. A. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413486842 · Cited by 132
Self-citationMulti-Day Low Dose Ketamine Infusion for the Treatment of Complex Regional Pain Syndrome
Goldberg, M. E. (2005) · Pain Physician · doi:10.36076/ppj.2005/8/175 · Cited by 127
Pilot dose–response trial of i.v. ketamine in treatment-resistant depression
Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., Harper, S., & Loo, C. K. A. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.922697 · Cited by 109
Self-citationTreatment of compulsive behaviour in eating disorders with intermittent ketamine infusions
Mills, I. G. (1998) · QJM · doi:10.1093/qjmed/91.7.493 · Cited by 87
Leptin/LepRb in the Ventral Tegmental Area Mediates Anxiety-Related Behaviors
Liu, J., Guo, M., & Lu, X. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv115 · Cited by 68
Neuromodulation Therapies for Geriatric Depression
Gálvez, V., Ho, K.-A., Alonzo, A., Martin, D. M., George, D., & Loo, C. K. A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0592-y · Cited by 66
Self-citationLong-term outcome of patients who receive ketamine during research
Lahti, A. C., Warfel, D. T., Michaelidis, T., Weiler, M. A., Frey, K., & Tamminga, C. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01037-4 · Cited by 53
Szymkowicz, S. M., Finnegan, N., & Dale, R. M. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000090 · Cited by 40
Gálvez, V., O’Keefe, E. J., Cotiga, L., Leyden, J., Harper, S., Glue, P., Mitchell, P. B., Somogyi, A. A., Delory, A., & Loo, C. K. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.010 · Cited by 40
Self-citationSrivastava, S., Gangwar, R. S., & Kumar, A. (2015) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.166627 · Cited by 19
SAFTEE: data system for side effect assessment scale.
Dj, C. (1986) · PubMed · Cited by 14
Cited by
Sorted by citations
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Novel and emerging treatments for major depression
Marwaha, S., Palmer, E. R., Suppes, T. M., Cons, E., Young, A. H., & Upthegrove, R. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 618
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Self-citationOchs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Metadata
- Authors
- George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., Harper, S., Brodaty, H., Glue, P., Taylor, R., Mitchell, P. B., & Loo, C. K.
- Affiliations
- Black Dog Institute (AU)
- UNSW Sydney (AU)
- Royal North Shore Hospital (AU)
- Wesley Hospital (AU)
- University of Otago (NZ)
- Corresponding author
- Loo, Colleen K.
- ORCID
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 25
- Issue
- 11
- Pages
- 1199-1209
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2625860417
- Cited by
- 149
- References
- 29
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 37 · 2023: 13 · 2022: 17 · 2021: 21 · 2020: 16 · 2019: 4 · 2018: 10 · 2017: 4
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NSW Institute of Psychiatry
- University of Barcelona
- NARSAD
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- subcutaneous ketamine, treatment-resistant depression, geriatric depression, older adults, dose titration, remission, relapse, psychotomimetic effects, antidepressant efficacy, drug safety
- MeSH terms
- Aged, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypnotics and Sedatives, Injections, Subcutaneous, Ketamine, Male, Midazolam, Middle Aged, Pilot Projects, Remission Induction, Outcome Assessment, Health Care, Cross-Over Studies, Excitatory Amino Acid Antagonists, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review